| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2500146 | Farmacia Hospitalaria | 2011 | 5 Pages |
Abstract
The treatment's effectiveness and safety in our patient group suggest that natalizumab is a treatment for refractory patients or those with aggressive types of multiple sclerosis, although we do not yet know about its long-term effects and the evolution of the appearance of neutralising antibodies.
Related Topics
Health Sciences
Pharmacology, Toxicology and Pharmaceutical Science
Pharmaceutical Science
Authors
M.J. Fernández-MegÃa, B. Casanova, M.J. Magraner, I. Font-Noguera, J.L. Poveda-Andrés,